Adoptive T cell therapy with CAR modified T cells: We have a Model A Ford, can we build a Ferrari?

被引：0
|
作者：
Brentjens, Renier [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷
关键词：
D O I：
10.1158/1557-3265.HEMMAL14-IA17
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IA17
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adoptive T cell therapy with CAR modified T cells: We have a model A Ford, can we build a Ferrari?
    Brentjens, Renier
    CANCER RESEARCH, 2015, 75
  • [2] CAR T cells - what have we learnt?
    不详
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (01) : 1 - 1
  • [3] CAR T cells — what have we learnt?
    Nature Reviews Clinical Oncology, 2018, 15 : 1 - 1
  • [4] CAR T cell therapy for multiple myeloma: What have we learned?
    Sandra Susanibar Adaniya
    Edward A. Stadtmauer
    Adam D. Cohen
    Leukemia, 2022, 36 : 1481 - 1484
  • [5] CAR T cell therapy for multiple myeloma: What have we learned?
    Adaniya, Sandra Susanibar
    Stadtmauer, Edward A.
    Cohen, Adam D.
    LEUKEMIA, 2022, 36 (06) : 1481 - 1484
  • [6] We Can't Have No Satisfaction
    Marques, Teresa
    FILOSOFIA UNISINOS, 2016, 17 (03): : 308 - 314
  • [7] CAR-T cell therapy: Where are we now, and where are we heading?
    Wang, Jia-Yi
    Wang, Liang
    BLOOD SCIENCE, 2023, 5 (04): : 237 - 248
  • [8] Adoptive immunotherapy with CAR-modified T cells
    Dotti, G.
    HUMAN GENE THERAPY, 2013, 24 (12) : A25 - A25
  • [9] How Can We Engineer CAR T Cells to Overcome Resistance?
    Glover, Maya
    Avraamides, Stephanie
    Maher, John
    BIOLOGICS-TARGETS & THERAPY, 2021, 15 : 175 - 198
  • [10] Can we reduce the acquisition cost of CAR T cell therapies?
    Schlander, M.
    Ran, T.
    Schmidt, P.
    Eichmueller, S. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S966 - S966
12345